Another approach to target tumor antigens in addition to disrupting the PD-1/PD-L1 interaction is the use of bicistronic CAR T cells (AUTO3) targeting the two antigens CD19 and CD22, followed by anti-PD-1 consolidation courses (NCT03287817) in patients with r/r DLBCL. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.